초록 ▼

According to the invention, gene products expressed in a tumor-associated manner and the nucleic acids coding therefor were identified. The invention relates to the therapy and diagnosis of diseases wherein said gene products expressed in a tumor-associated manner are aberrantly expressed. The inven

According to the invention, gene products expressed in a tumor-associated manner and the nucleic acids coding therefor were identified. The invention relates to the therapy and diagnosis of diseases wherein said gene products expressed in a tumor-associated manner are aberrantly expressed. The invention also relates to proteins, polypeptides and peptides which are expressed in a tumor associated manner and to nucleic acids coding therefor.

대표청구항 ▼

1. A purified antibody or an antigen binding fragment thereof that binds to a tumor-associated antigen selected from the group consisting of: a tumor-associated antigen comprising the amino acid sequence of SEQ ID NO: 16; wherein binding of said antibody to said tumor-associated antigen is prevented

1. A purified antibody or an antigen binding fragment thereof that binds to a tumor-associated antigen selected from the group consisting of: a tumor-associated antigen comprising the amino acid sequence of SEQ ID NO: 16; wherein binding of said antibody to said tumor-associated antigen is prevented by glycosylation at a glycosylation site of said tumor-associated antigen. 2. The purified antibody of claim 1, wherein the amino acid position of said glycosylation site is selected from the group consisting of positions 37, 38, 45, 116, 141, 146 and 205 of SEQ ID NO: 16. 3. The purified antibody of any one of claims 1 to 2 that is a monoclonal, chimeric, or humanized antibody. 4. A conjugate between the purified antibody or an antigen binding fragment thereof of any one of claims 1 to 2 and at least one therapeutic agent. 5. The conjugate of claim 4, wherein said therapeutic agent is a toxin. 6. The conjugate of claim 4, wherein said therapeutic agent is selected from the group consisting essentially of aminoglutethimide, azathioprine, bleomycin sulfate, busulfan, carmustine, chlorambucil, cisplatin, cyclophosphamide, cyclosporine, cytarabidine, dacarbazine, dactinomycin, daunorubin, doxorubicin, taxol, etoposide, fluorouracil, interferon-α, lomustine, mercaptopurine, methotrexate, mitotane, procarbazine hydrochloride, thioguanine, vinblastine sulfate, and vincristine sulfate. 7. A pharmaceutical composition comprising the purified antibody or antigen binding fragment thereof of any one of claims 1 to 2 and a pharmaceutically compatible carrier. 8. The pharmaceutical composition of claim 7, wherein the purified antibody causes induction of cell death, reduction in cell growth, cell membrane damage, or secretion of cytokines. 9. The pharmaceutical composition of claim 7, wherein said purified antibody is a complement-activating antibody, a monoclonal antibody, a chimeric antibody, or a humanized antibody. 10. The pharmaceutical composition of claim 7, wherein said purified antibody is coupled to a therapeutic agent. 11. The pharmaceutical composition of claim 10, wherein said therapeutic agent is a toxin. 12. The pharmaceutical composition of claim 10, wherein said therapeutic agent is selected from the group consisting essentially of aminoglutethimide, azathioprine, bleomycin sulfate, busulfan, carmustine, chlorambucil, cisplatin, cyclophosphamide, cyclosporine, cytarabidine, dacarbazine, dactinomycin, daunorubin, doxorubicin, taxol, etoposide, fluorouracil, interferon-α, lomustine, mercaptopurine, methotrexate, mitotane, procarbazine hydrochloride, thioguanine, vinblastine sulfate and vincristine sulfate.